DK368588A - Bindingsmolekyler med en enkelt polypeptidkaede - Google Patents

Bindingsmolekyler med en enkelt polypeptidkaede

Info

Publication number
DK368588A
DK368588A DK368588A DK368588A DK368588A DK 368588 A DK368588 A DK 368588A DK 368588 A DK368588 A DK 368588A DK 368588 A DK368588 A DK 368588A DK 368588 A DK368588 A DK 368588A
Authority
DK
Denmark
Prior art keywords
molecule
binding molecules
chain
polypeptid
binding specificity
Prior art date
Application number
DK368588A
Other languages
English (en)
Other versions
DK368588D0 (da
Inventor
Robert Charles Ladner
Robert Earl Bird
Original Assignee
Genex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genex Corp filed Critical Genex Corp
Publication of DK368588D0 publication Critical patent/DK368588D0/da
Publication of DK368588A publication Critical patent/DK368588A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Adhesives Or Adhesive Processes (AREA)
DK368588A 1986-09-02 1988-07-01 Bindingsmolekyler med en enkelt polypeptidkaede DK368588A (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90297186A 1986-09-02 1986-09-02
PCT/US1987/002208 WO1988001649A1 (en) 1986-09-02 1987-09-02 Single polypeptide chain binding molecules
CA000546164A CA1341364C (en) 1986-09-02 1987-09-04 Single polypeptide chain binding molecules

Publications (2)

Publication Number Publication Date
DK368588D0 DK368588D0 (da) 1988-07-01
DK368588A true DK368588A (da) 1988-07-01

Family

ID=25671493

Family Applications (1)

Application Number Title Priority Date Filing Date
DK368588A DK368588A (da) 1986-09-02 1988-07-01 Bindingsmolekyler med en enkelt polypeptidkaede

Country Status (7)

Country Link
EP (1) EP0281604B1 (da)
JP (1) JPH02197A (da)
AT (1) ATE87659T1 (da)
CA (1) CA1341364C (da)
DE (1) DE3785186T2 (da)
DK (1) DK368588A (da)
WO (1) WO1988001649A1 (da)

Families Citing this family (490)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU612370B2 (en) * 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
CA1341411C (en) * 1988-04-16 2002-12-17 Lutz Riechmann Method for producing fv fragments in eukaryotic cells
US5965405A (en) * 1988-04-16 1999-10-12 Celltech Limited Method for producing Fv fragments in eukaryotic cells
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
US6291160B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US6416971B1 (en) 1990-05-15 2002-07-09 E.R. Squibb & Sons, Inc. Soluble single chain T cell receptors
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5912170A (en) * 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US5843728A (en) * 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US6027725A (en) * 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0672068A4 (en) * 1992-09-25 1997-02-26 Commw Scient Ind Res Org TARGET MOLECULES BINDING POLYPEPTIDES.
AU5670194A (en) * 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US6017697A (en) 1994-11-14 2000-01-25 Eli Lilly And Company Excitatory amino acid receptor protein and related nucleic acid compounds
JP4503706B2 (ja) 1996-06-07 2010-07-14 ポニアード ファーマシューティカルズ，インコーポレイティド グリコシル化が改質されたヒト化抗体
CA2266339A1 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
GB9705376D0 (en) * 1997-03-14 1997-04-30 Harris William J Antibody fragment formulations and assay formats for detecting the presence an d concentration of analytes
JP3556459B2 (ja) 1998-03-13 2004-08-18 セイコープレシジョン株式会社 Ｅｌモジュール
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
CA2451955C (en) 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
WO2003062370A2 (en) 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
EP2314316A1 (en) 2002-04-05 2011-04-27 Amgen, Inc Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
CN104178491B (zh) 2002-09-06 2018-07-03 安姆根有限公司 治疗性人抗-il-1r1单克隆抗体
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
WO2004034988A2 (en) 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
NZ544797A (en) 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
EP1498133A1 (en) 2003-07-18 2005-01-19 Aventis Pharma Deutschland GmbH Use of a pak inhibitor for the treatment of a joint disease
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
PT2380985E (pt) 2003-09-23 2014-03-26 Univ North Carolina Células que expressam a vitamina k epóxido reductase e sua utilização
DK2189523T3 (da) 2003-10-14 2012-03-12 Baxter Int VKORC1 (vitamin K-epoxid-tilbageføringspolypeptid), et terapeutisk mål for coumarin og dets derivater
AU2005205412B2 (en) 2004-01-20 2011-08-11 Merus N.V. Mixtures of binding proteins
ES2442386T3 (es) 2004-04-23 2014-02-11 Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
CA2574881C (en) 2004-08-04 2013-01-08 Amgen Inc. Antibodies to dkk-1
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
BRPI0606432A2 (pt) 2005-01-07 2009-06-30 Lexicon Pharmaceuticals Inc anticorpos monoclonais contra angptl4
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
KR101338885B1 (ko) 2005-03-11 2013-12-12 사노피 Mgc4504의 용도
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
BRPI0611069A2 (pt) 2005-05-06 2010-11-09 Zymogenetics Inc anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
EP1882044A1 (en) 2005-05-11 2008-01-30 sanofi-aventis Use of a gip promoter polymorphism
EP1888052A2 (en) 2005-05-12 2008-02-20 Wisconsin Alumni Research Foundation Blockade of pin1 prevents cytokine production by activated immune cells
DK1915398T3 (da) 2005-07-18 2016-07-04 Amgen Inc Humane anti-B7RP1 neutraliserende antistoffer
SI1933869T1 (sl) 2005-09-01 2010-02-26 Schering Corp Uporaba IL-23 in IL-17 antagonistov za zdravljenje avtoimunske očesne vnetne bolezni
DE102005048898A1 (de) 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
EP2805971A1 (en) 2005-11-28 2014-11-26 ZymoGenetics, Inc. IL-21 antagonists
WO2007070948A1 (en) 2005-12-20 2007-06-28 Arana Therapeutics Limited Anti-inflammatory dab
AU2007249713A1 (en) 2006-01-10 2007-11-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31Ra and OSMRb antagonists
CN103232540A (zh) 2006-02-01 2013-08-07 赛法隆澳大利亚控股有限公司 结构域抗体构建体
WO2007106769A2 (en) 2006-03-10 2007-09-20 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
CN103073639A (zh) 2006-03-17 2013-05-01 比奥根艾迪克Ma公司 稳定的多肽组合物
AU2007279205B2 (en) 2006-07-28 2013-09-26 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
CN103044550A (zh) 2006-09-01 2013-04-17 津莫吉尼蒂克斯公司 Il-31单克隆抗体的可变区序列和使用方法
RU2009122514A (ru) 2006-11-17 2010-12-27 Новартис АГ (CH) Молекулы, связывающие белок lingo, и их фармацевтическое применение
WO2008073300A2 (en) 2006-12-08 2008-06-19 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
CA2679400A1 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
ES2465223T3 (es) 2007-04-27 2014-06-05 Zymogenetics, Inc. Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso
CA2691075C (en) 2007-06-15 2017-04-11 Daniela Gast Treatment of tumors using specific anti-l1 antibody
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
EP2023144A1 (en) 2007-08-01 2009-02-11 Sanofi-Aventis Novel AS160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
RS56743B1 (sr) 2007-08-21 2018-03-30 Amgen Inc Humani c-fms antigen vezujući proteini
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP4248976B1 (en) 2007-08-23 2026-04-22 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US8629246B2 (en) 2007-09-26 2014-01-14 Ucb Pharma S.A. Dual specificity antibody fusions
AU2008317724B2 (en) 2007-11-02 2011-06-02 Novartis Ag Improved Nogo-A binding molecules and pharmaceutical use thereof
US8715941B2 (en) 2007-11-16 2014-05-06 Arca Biopharma, Inc. Antibodies to LRP6
WO2009079212A2 (en) 2007-12-03 2009-06-25 Carnegie Mellon University Linked peptide fluorogenic biosensors
KR101603109B1 (ko) 2007-12-07 2016-03-25 지모제넥틱스, 인코포레이티드 Ｉｌ-31에 특이적인 인간화된 항체 분자
EP2105742A1 (en) 2008-03-26 2009-09-30 Sanofi-Aventis Use of cathepsin C
ES2456296T3 (es) 2008-03-27 2014-04-21 Zymogenetics, Inc. Composiciones y procedimientos para inhibir PDGFR beta y VEGF-A
US8518410B2 (en) 2009-03-10 2013-08-27 Baylor Research Institute Fusion protein with HIV antigen
WO2010035012A1 (en) 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP2219029A1 (en) 2009-01-30 2010-08-18 Sanofi-Aventis Test systems, methods and uses involving AS160 protein
AU2010220421B9 (en) 2009-03-02 2015-03-05 Aduro Biotech Holdings, Europe B.V. Antibodies against a proliferating inducing ligand (APRIL)
AU2010222942B2 (en) 2009-03-10 2013-01-10 Baylor Research Institute Anti-CD40 antibodies and uses thereof
EP2406288B1 (en) 2009-03-10 2016-12-14 Baylor Research Institute Antigen presenting cell targeted vaccines
EP3385279B1 (en) 2009-03-20 2020-02-26 Amgen Inc. Carrier immunoglobulins and uses thereof
AU2010249470B2 (en) 2009-05-20 2015-06-25 Novimmune S.A. Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
IN2012DN00863A (da) 2009-07-31 2015-07-10 Medarex Inc
EP2293072A1 (en) 2009-08-31 2011-03-09 Sanofi-Aventis Use of cathepsin H
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
JP5888728B2 (ja) 2009-11-05 2016-03-22 国立大学法人大阪大学 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
US9995679B2 (en) 2010-05-25 2018-06-12 Carnegie Mellon University Targeted probes of cellular physiology
PL2575881T3 (pl) 2010-05-28 2018-06-29 Inserm - Institut National De La Santé Et De La Recherche Médicale Przeciwciała swoiste wobec CD160 do leczenia zaburzeń oczu związanych z angiogenezą
JP6023706B2 (ja) 2010-07-09 2016-11-09 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Ｃｄ２７に対するアゴニスト抗体
KR102024922B1 (ko) 2010-07-16 2019-09-25 아디맵 엘엘씨 항체 라이브러리
JP2013535692A (ja) 2010-08-10 2013-09-12 アムジエン・インコーポレーテツド 標的抗体に対する中和抗体検出用インビトロ二重機能標的結合アッセイ
EP2619226B1 (en) 2010-09-22 2018-09-12 Amgen Inc. Carrier immunoglobulins and uses thereof
TWI636993B (zh) 2010-10-27 2018-10-01 安美基公司 Ｄｋｋ１抗體及使用方法
TWI638833B (zh) 2010-11-30 2018-10-21 中外製藥股份有限公司 細胞傷害誘導治療劑
TW201241179A (en) 2010-12-17 2012-10-16 Sanofi Sa MiRNAs in joint disease
UY33807A (es) 2010-12-17 2012-07-31 Sanofi Sa miRNAs como indicadores del estado tisular o de enfermedades como osteoartritis
TW201239097A (en) 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
TW201238974A (en) 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
EP2668207A4 (en) 2011-01-24 2015-06-10 Univ Singapore MANNOSE-CAPTURED LIPOARABINOMANANE ANTIGEN-BINDING PROTEINS OBTAINED FROM ILLNESSIFYING MYCOBACTERIES
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
US9340590B2 (en) 2011-03-16 2016-05-17 Amgen Inc. Potent and selective inhibitors of NaV1.3 and NaV1.7
TW201300418A (zh) 2011-03-25 2013-01-01 Baylor Res Inst 用於抗ｃ型肝炎病毒免疫之組合物及方法
PE20140964A1 (es) 2011-03-30 2014-08-17 Boehringer Ingelheim Int Antidotos anticoagulantes
US8628773B2 (en) 2011-04-07 2014-01-14 Amgen Inc. Antigen binding proteins
KR101338517B1 (ko) 2011-04-18 2013-12-10 연세대학교 산학협력단 인간 간-카르복실에스터라제 １을 특이적으로 인식하는 단일클론 항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도
EP2518157A1 (en) 2011-04-26 2012-10-31 Sanofi Test Systems and methods for identifying a compound altering cellular DDR activity
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EP2537532A1 (en) 2011-06-22 2012-12-26 J. Stefan Institute Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
CA2858572C (en) 2011-12-08 2023-01-17 Amgen Inc. Human lcat antigen binding proteins and their use in therapy
US9546219B2 (en) 2012-02-08 2017-01-17 North Carolina State University Treatment of allergic diseases with recombinant antibodies
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
DK3431492T3 (da) 2012-04-27 2021-03-08 Amgen Inc Humane cd30-ligandantigen-bindende proteiner
US9090694B2 (en) 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
EA201492282A1 (ru) 2012-06-11 2015-07-30 Амген Инк. Антагонистические антигенсвязывающие белки к двум рецепторам и их применение
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
ES2831374T3 (es) 2012-11-21 2021-06-08 Janssen Biotech Inc Anticuerpos de EGFR/c-Met biespecíficos
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
WO2014144553A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
JP6469644B2 (ja) 2013-03-15 2019-02-13 アムジエン・インコーポレーテツド 抗ｃｃｒ７抗原結合タンパク質に関係する方法および組成物
US9902770B2 (en) 2013-03-15 2018-02-27 Janssen Biotech, Inc. Interferon alpha and omega antibody antagonists
TWI636064B (zh) 2013-03-15 2018-09-21 安美基公司 人類ｐａｃ１抗體
KR101453462B1 (ko) 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
CA2916259C (en) 2013-06-28 2024-02-20 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
RU2016107426A (ru) 2013-08-02 2017-09-07 Адуро Байотек Холдингс, Юроуп Б.В. Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета
CA2920376A1 (en) 2013-08-07 2015-02-12 Martin Blomberg JENSEN Methods and composition comprising denosumab or an antibody or antigen binding domain, fragment or derivative thereof, immunoreactive with a rankl/opgbp peptide for use in the treatment, prevention or alleviation of male infertility
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
JP2016531920A (ja) 2013-09-05 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Ｃｄ７０結合ペプチドおよびそれに関連する方法、プロセスおよび用途
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
PL3065774T3 (pl) 2013-11-06 2021-12-13 Janssen Biotech, Inc Przeciwciała anty-ccl17
EP4124624A3 (en) 2013-12-20 2023-05-03 Intervet International B.V. Antibodies against canine pd-1
JP2017502672A (ja) 2013-12-30 2017-01-26 メディシナル バイオコンバージェンス リサーチ センター 抗ｋｒｓモノクロナル抗体及びこれの用途
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
EP3094652B1 (en) 2014-01-13 2021-09-29 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CR20170060A (es) 2014-08-19 2017-04-18 Merck Sharp & Dohme Anticuerpos anti tigit
PE20170676A1 (es) 2014-09-09 2017-05-22 Janssen Biotech Inc Terapias de combinacion con anticuerpos anti-cd38
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US10434177B2 (en) 2014-11-17 2019-10-08 Carnegie Mellon University Activatable two-component photosensitizers
CN107108743B (zh) 2014-12-03 2021-05-04 (株)爱恩德生物 结合神经毡蛋白1的抗体及其用途
EA202092609A1 (ru) 2014-12-04 2021-10-29 Янссен Байотек, Инк. Антитела к cd38 для лечения острого миелолейкоза
WO2016100615A2 (en) 2014-12-18 2016-06-23 The University Of Chicago Methods and composition for neutralization of influenza
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
EP3085709B1 (en) 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
DK3244911T3 (da) 2015-01-12 2019-12-16 Rigshospitalet Copenhagen Univ Hospital Fremgangsmåde til bestemmelse af en sandsynlig virkning af en behandling til forbedring af mandlig ufrugtbarhed
US10765699B2 (en) 2015-02-06 2020-09-08 National University Of Singapore Methods for enhancing efficacy of therapeutic immune cells
EP3265179A4 (en) 2015-03-04 2018-07-18 The University of Chicago Beta-catenin inhibitors in cancer immunotherapy
JP6938383B2 (ja) 2015-04-02 2021-09-22 インターベット インターナショナル ベー． フェー． イヌインターロイキン４受容体アルファに対する抗体
CA2986594C (en) 2015-05-20 2025-06-10 Tufts Medical Center, Inc. Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
WO2016196605A1 (en) 2015-06-01 2016-12-08 The University Of Chicago Treatment of cancer by manipulation of commensal microflora
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
HRP20240338T1 (hr) 2015-06-24 2024-05-24 Janssen Biotech, Inc. Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EA201890434A1 (ru) 2015-08-05 2018-10-31 Янссен Байотек, Инк. Антитела к cd154 и способы их применения
BR112018006360A2 (pt) 2015-09-30 2018-10-09 Janssen Biotech Inc anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
HUE053366T2 (hu) 2015-11-03 2021-06-28 Janssen Biotech Inc Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
KR20250099459A (ko) 2015-11-03 2025-07-01 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 그의 용도
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
KR101896882B1 (ko) 2015-11-30 2018-09-11 앱클론(주) Vegfr2에 특이적으로 결합하는 항체
JP7000322B2 (ja) 2015-12-16 2022-02-04 メルク・シャープ・アンド・ドーム・コーポレーション 抗ｌａｇ３抗体および抗原結合性フラグメント
WO2017106684A2 (en) 2015-12-17 2017-06-22 Janssen Biotech, Inc. Antibodies specifically binding hla-dr and their uses
CR20180378A (es) 2015-12-23 2018-12-06 Amgen Inc Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
US20170198290A1 (en) 2016-01-08 2017-07-13 Northwestern University Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (klc1c)
WO2017132376A1 (en) 2016-01-27 2017-08-03 Just Biotherapeutics, Inc. Hybrid promoter and uses thereof
CA3011942A1 (en) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Psma and cd3 bispecific t cell engaging antibody constructs
SG11201805770UA (en) 2016-02-03 2018-08-30 Amgen Res Munich Gmbh BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
JP6795603B2 (ja) 2016-02-15 2020-12-02 サムソン ライフ パブリック ウェルフェア ファウンデーション ＥＧＦＲｖＩＩＩ（Ｅｐｉｄｅｒｍａｌ Ｇｒｏｗｔｈ Ｆａｃｔｏｒ Ｒｅｃｅｐｔｏｒ Ｖａｒｉａｎｔ ＩＩＩ）に対する抗体およびその用途
CA3016424A1 (en) 2016-03-14 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US10689450B2 (en) 2016-04-01 2020-06-23 Kite Pharma, Inc BCMA binding molecules and methods of use thereof
KR102694879B1 (ko) 2016-04-01 2024-08-16 암젠 인크 Flt3에 대한 키메라 수용체 및 이의 사용 방법
US10603380B2 (en) 2016-04-01 2020-03-31 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
KR102608405B1 (ko) 2016-04-01 2023-12-01 카이트 파마 인코포레이티드 키메라 수용체 및 그의 사용 방법
CA3019588A1 (en) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
UA127200C2 (uk) 2016-05-18 2023-06-07 Бьорінгер Інгельхайм Інтернаціональ Гмбх Молекула антитіла до pd1
WO2017204606A1 (ko) 2016-05-27 2017-11-30 오름테라퓨틱 주식회사 세포질 침투 항체 및 이의 용도
WO2017209554A2 (ko) 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 항-nrp1 항체 스크리닝 방법
WO2017209553A2 (ko) 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 환자 유래 세포를 이용한 항체 스크리닝 방법
AU2017273169B2 (en) 2016-06-03 2020-07-30 Aimed Bio Inc. Method for screening antibody using patient-derived tumor spheroids
EP3467508A4 (en) 2016-06-03 2020-04-29 Samsung Life Public Welfare Foundation Anti-nrp1 antibody screening method
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
EP3487506A1 (en) 2016-07-20 2019-05-29 Hybrigenics SA Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
RU2721582C1 (ru) 2016-08-05 2020-05-20 И-Байолоджикс Инк. Антитела против лиганда-1 запрограммированной смерти (PD-L1) и их применение
WO2018026249A1 (ko) 2016-08-05 2018-02-08 주식회사 와이바이오로직스 프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도
AU2017306506B2 (en) 2016-08-05 2020-05-21 Y-Biologics Inc. Antibody to programmed cell death 1 (PD-1) and use thereof
JP7009448B2 (ja) 2016-08-12 2022-02-10 ヤンセン バイオテツク，インコーポレーテツド 強化されたアゴニスト活性を有する、Ｆｃが遺伝子操作を受けた抗ＴＮＦＲスーパーファミリーメンバー抗体及びその使用方法
MA45919A (fr) 2016-08-12 2019-06-19 Janssen Biotech Inc Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
EP3515503B1 (en) 2016-09-23 2025-10-29 The Regents Of The University Of Michigan Engineered lymphocytes
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
US10941195B2 (en) 2016-10-04 2021-03-09 Fairbanks Pharmaceuticals, Inc. Anti-follistatin-like 3 antibodies and treatment of diabetes
CN110352073A (zh) 2016-10-28 2019-10-18 机敏医药股份有限公司 针对timp-2的抗体用于改善肾功能的用途
EP3538558A4 (en) 2016-11-09 2020-07-15 North Carolina State University TREATMENT OF ALLERGIC DISEASES USING CHIMERIC PROTEIN
CA3043487A1 (en) 2016-11-21 2018-05-24 Just-Evotec Biologics Inc Aflibercept formulations and uses thereof
US10759855B2 (en) 2016-12-02 2020-09-01 Rigel Pharmaceuticals, Inc. Antigen binding molecules to TIGIT
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
JP7681879B2 (ja) 2016-12-22 2025-05-23 ウニヴェルシタ・デリ・ストゥディ・マニャ・グレチア・カタンツァーロ Ｃｄ４３の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体
CN106519034B (zh) 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 抗pd-1抗体及其用途
CA3048186A1 (en) 2016-12-23 2018-06-28 Cephalon, Inc. Anti-il-5 antibodies
KR102781241B1 (ko) 2017-01-17 2025-03-14 암젠 인크 위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법
AU2018214223B2 (en) 2017-02-02 2025-08-14 Amgen Inc. Low pH pharmaceutical composition comprising T cell engaging antibody constructs
JP7141405B2 (ja) 2017-02-09 2022-09-22 プロメガ コーポレイション 検体検出イムノアッセイ
WO2018160917A1 (en) 2017-03-03 2018-09-07 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
WO2018190719A2 (en) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
KR102700015B1 (ko) 2017-05-05 2024-08-29 암젠 인크 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물
AU2018278730B2 (en) 2017-05-30 2021-02-04 Chong Kun Dang Pharmaceutical Corp. A novel anti-c-Met antibody and use thereof
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
EP3634443B1 (en) 2017-06-05 2024-09-18 The University of Chicago Microbiome biomarkers of immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof
AU2018281045A1 (en) 2017-06-05 2019-12-12 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
CR20190550A (es) 2017-06-05 2020-04-05 Janssen Biotech Inc Anticuerpos que se unen específicamente a pd-1 y métodos de uso
MX2019013919A (es) 2017-06-20 2020-01-21 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
JP7250706B2 (ja) 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
FI3661562T3 (fi) 2017-08-04 2024-12-09 Amgen Inc Cys-mab:ien konjugointimenetelmä
CA3074317C (en) 2017-08-25 2024-06-18 Janssen Biotech, Inc. Fc.gamma.rii binding fibronectin type iii domains, their conjugates and multispecific molecules comprising them
KR102521245B1 (ko) 2017-09-15 2023-04-17 카이트 파마 인코포레이티드 관리 연속성 및 신원 연속성 생물학적 샘플 추적으로 환자-특이적 면역요법 절차를 수행하기 위한 방법 및 시스템
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
SG11202003114UA (en) 2017-10-04 2020-05-28 Amgen Inc Transthyretin immunoglobulin fusions
US11598780B2 (en) 2017-10-06 2023-03-07 The University Of Chicago Engineering lymphocytes with specific alpha and beta chains on their t-cell receptor
WO2019075216A1 (en) 2017-10-11 2019-04-18 Iti Health, Inc. D/B/A Zielbio ANTIBODIES BINDING TO PELTIN-1 AND USES THEREOF
MX2020005495A (es) 2017-10-20 2021-01-08 Pharmabcine Inc Anticuerpo anti-vista y uso del mismo.
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
WO2019099965A1 (en) 2017-11-20 2019-05-23 Just Biotherapeutics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
TWI827570B (zh) 2017-12-11 2024-01-01 美商安進公司 雙特異性抗體產品之連續製造製程
KR102311838B1 (ko) 2017-12-27 2021-10-14 주식회사 파멥신 항-pd-l1 항체 및 이의 용도
EP3732195A4 (en) 2017-12-28 2022-02-09 Chugai Seiyaku Kabushiki Kaisha CYTOTOXICITY-INDUCING THERAPEUTIC
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
US11304988B2 (en) 2018-01-24 2022-04-19 Northwestern University Inhibiting tumor cell migration by inhibition of kinesin light chain 1, variant 1 (KLC1C)
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
EP3758749A4 (en) 2018-03-02 2022-07-06 The University of Chicago METHOD AND COMPOSITION FOR NEUTRALIZING INFLUENZA
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
KR102275930B1 (ko) 2018-03-14 2021-07-12 (주)알테오젠 Folr1에 특이적으로 결합하는 항체 및 그의 용도
WO2019183094A1 (en) 2018-03-19 2019-09-26 The Regents Of The University Of Michigan Compositions and methods for t-cell and cytokine activation
US12060437B2 (en) 2018-03-23 2024-08-13 North Carolina State University Methods and compositions for antibody to high affinity receptor for IgE
UY38182A (es) 2018-04-10 2019-10-31 Amgen Inc Receptores quiméricos de dll3 y métodos para su uso
CN111886023B (zh) 2018-04-24 2024-09-27 安源医药科技（上海）有限公司 针对tim-3的抗体及其用途
CN112469826B (zh) 2018-04-27 2024-02-09 (株)爱恩德生物 通过磁珠附着至细胞进行的基于磁性的生物淘选方法
MA52571A (fr) 2018-05-08 2021-03-17 Amgen Inc Anticorps bispécifiques ayant des étiquettes appairées à des charges c-terminales clivables
SG11202011306TA (en) 2018-05-16 2020-12-30 Janssen Biotech Inc Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
EP3784776A4 (en) 2018-05-23 2022-01-26 National University of Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
CN112912397B (zh) 2018-05-24 2025-03-14 詹森生物科技公司 抗cd3抗体及其用途
MA52777A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Agents de liaison psma et utilisations correspondantes
CR20200564A (es) 2018-05-24 2021-06-21 Janssen Biotech Inc Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos
KR102115300B1 (ko) 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CN112119094B (zh) 2018-06-29 2024-11-22 Y生物股份有限公司 与淋巴细胞活化基因3特异性结合的单克隆抗体及其用途
JP7459046B2 (ja) 2018-07-18 2024-04-01 アムジエン・インコーポレーテツド Ｓｔｅａｐ１に対するキメラ受容体及びその使用方法
EP3830124A1 (en) 2018-08-01 2021-06-09 Cephalon, Inc. Anti-cxcr2 antibodies and uses thereof
AU2019315226B2 (en) 2018-08-03 2025-09-18 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing two antigen-binding domains that are linked to each other
KR102842215B1 (ko) 2018-08-10 2025-08-05 주식회사 유틸렉스 Hla-dr에 결합하는 키메라 항원 수용체 및 car-t 세포
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
RS65658B1 (sr) 2018-08-27 2024-07-31 Affimed Gmbh Kriokonzervirane nk ćelije prethodno punjene konstruktom antitela
CN112672760B (zh) 2018-09-13 2025-05-30 德克萨斯大学体系董事会 新颖lilrb4抗体和其用途
AR117650A1 (es) 2018-10-11 2021-08-18 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecíficos
BR112021007227A2 (pt) 2018-10-17 2021-08-10 Janssen Biotech, Inc. método para fornecer administração subcutânea de anticorpos anti-cd38
JP7410143B2 (ja) 2018-11-01 2024-01-09 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 二重特異性抗体及びその用途
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
AU2019379858B2 (en) 2018-11-13 2024-01-04 Janssen Biotech, Inc. Control of trace metals during production of anti-CD38 antibodies
CN120519520A (zh) 2018-11-14 2025-08-22 麦迪赛克斯医疗私人有限公司 用于生成car-t细胞的两类基因载体及其用途
WO2020113036A2 (en) 2018-11-28 2020-06-04 Promega Corporation Reactive peptide labeling
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
WO2020135710A1 (zh) 2018-12-27 2020-07-02 中山康方生物医药有限公司 抗人il-4ra的抗体及其用途
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020159836A1 (en) 2019-01-28 2020-08-06 Maple Biotech Llc Psmp antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
EP3920975A4 (en) 2019-02-06 2022-09-21 The Regents of The University of Michigan Chimeric antigen receptors targeting abnormal glycobiology
US11254736B2 (en) 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations
EP3924458A1 (en) 2019-02-15 2021-12-22 Just-Evotec Biologics, Inc. Automated biomanufacturing systems, facilities, and processes
CN121971599A (zh) 2019-02-25 2026-05-05 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
MX2021010453A (es) 2019-03-06 2021-09-21 Legochem Biosciences Inc Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos.
US11541086B2 (en) 2019-03-14 2023-01-03 Northwestern Univeristy Compositions and methods for treating Alzheimer's disease
WO2020191339A1 (en) 2019-03-20 2020-09-24 Promega Corporation Photoaffinity probes
AR118720A1 (es) 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
AU2020259405A1 (en) 2019-04-19 2021-09-23 Janssen Biotech, Inc. Methods of treating renal cancer with an anti- PSMA/CD3 antibody
PH12021552798A1 (en) 2019-05-14 2022-09-19 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
CN114206355A (zh) 2019-06-03 2022-03-18 芝加哥大学 用靶向癌症的佐剂治疗癌症的方法和组合物
JPWO2020246563A1 (da) 2019-06-05 2020-12-10
AU2020290573B2 (en) 2019-06-13 2026-01-29 Amgen Inc. Automated biomass-based perfusion control in the manufacturing of biologics
KR20220041080A (ko) 2019-06-18 2022-03-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(hbv) 백신 및 항-pd-1 또는 항-pc-l1 항체의 조합
AU2020296372A1 (en) 2019-06-18 2022-02-17 Janssen Sciences Ireland Unlimited Company Combination of hepatitis B virus (HBV) vaccines and anti-PD-1 antibody
SG11202112762TA (en) 2019-07-08 2021-12-30 Amgen Inc Multispecific transthyretin immunoglobulin fusions
PH12021552960A1 (en) 2019-07-10 2022-07-25 Chugai Pharmaceutical Co Ltd Claudin-6 binding molecules and uses thereof
CN114401741A (zh) 2019-07-11 2022-04-26 拓维创新生物科技(香港)有限公司 干扰胸腺基质淋巴细胞生成素(tslp)受体信号传导的药剂
CA3145345A1 (en) 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies against canine ctla-4
MX2022001305A (es) 2019-07-30 2022-05-06 Akeso Biopharma Inc Anticuerpo de dominio proteínico p40 anti-humana y uso del mismo.
US20220324971A1 (en) 2019-09-03 2022-10-13 Akeso Biopharma, Inc Anti-cd47 monoclonal antibody and use thereof
EP4025606A1 (en) 2019-09-04 2022-07-13 Y-Biologics Inc. Anti-vsig4 antibody or antigen binding fragment and uses thereof
US20220306741A1 (en) 2019-09-10 2022-09-29 Amgen Inc. Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity
US11760801B2 (en) 2019-09-27 2023-09-19 Janssen Biotech, Inc. Anti-CEACAM antibodies and uses thereof
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
CN115175680A (zh) 2019-10-18 2022-10-11 加利福尼亚大学董事会 Plxdc激活剂及其用于治疗血管病症的用途
US20220403038A1 (en) 2019-11-07 2022-12-22 Amgen Inc. Method of treating or ameliorating cushing's syndrome using binding proteins for gastric inhibitory peptide receptor (gipr)
CA3156683A1 (en) 2019-11-13 2021-05-20 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
CN114980920A (zh) 2019-11-18 2022-08-30 詹森生物科技公司 基于突变体calr和jak2的疫苗及其用途
US12241839B2 (en) 2019-11-27 2025-03-04 Promega Corporation Multipartite luciferase peptides and polypeptides
EP4069291A1 (en) 2019-12-03 2022-10-12 Evotec International GmbH Interferon-associated antigen binding proteins and uses thereof
JP2023505169A (ja) 2019-12-03 2023-02-08 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｂ型肝炎感染の治療における使用のためのインターフェロン会合抗原結合タンパク質
EP4073512B1 (en) 2019-12-10 2025-11-12 Promega Corporation Compositions and methods for bioluminescent detection using multifunctional probes
KR20230015874A (ko) 2019-12-17 2023-01-31 치누크 세라퓨틱스, 인크. 아트라센탄에 의해 iga 신장병증을 치료하는 방법
AU2020407124A1 (en) 2019-12-20 2022-07-21 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1
AU2020414409A1 (en) 2019-12-27 2022-06-16 Affimed Gmbh Method for the production of bispecific FcyRIIl x CD30 antibody construct
JP7783182B2 (ja) 2020-02-12 2025-12-09 ヤンセン バイオテツク，インコーポレーテツド ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
TWI900527B (zh) 2020-02-12 2025-10-11 比利時商健生藥品公司 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
MX2022011632A (es) 2020-03-19 2022-10-13 Amgen Inc Anticuerpos contra mucina 17 y usos de los mismos.
JP7736688B2 (ja) 2020-03-31 2025-09-09 中外製薬株式会社 多重特異性抗原結合分子を製造するための方法
JP7692404B2 (ja) 2020-04-02 2025-06-13 中外製薬株式会社 多重特異性抗原結合分子を含む組成物における不純物分子の分析方法
IL297806A (en) 2020-04-30 2022-12-01 Sairopa B V Anti-cd103 antibodies
PH12022553023A1 (en) 2020-05-11 2024-03-04 Janssen Biotech Inc Methods for treating multiple myeloma
CN115666727A (zh) 2020-05-19 2023-01-31 詹森生物科技公司 包含t细胞重定向治疗剂和vla-4粘附途径抑制剂的组合物
US12312412B2 (en) 2020-05-19 2025-05-27 Amgen Inc. MAGEB2 binding constructs
CA3180665A1 (en) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
CA3184189A1 (en) 2020-05-27 2021-12-02 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
US20230235080A1 (en) 2020-06-03 2023-07-27 Bionecure Therapeutics, Inc. Trophoblast cell-surface antigen-2 (trop-2) antibodies
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230256114A1 (en) 2020-07-07 2023-08-17 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
WO2022023292A2 (en) 2020-07-31 2022-02-03 Friedrich-Alexander-Universität Erlangen-Nürnberg Corona virus spike protein-targeting antibodies and use thereof
CN116194124A (zh) 2020-07-31 2023-05-30 中外制药株式会社 包含表达嵌合受体的细胞的药物组合物
US12528869B2 (en) 2020-08-25 2026-01-20 Janssen Biotech, Inc. Treatment of non-small cell lung cancer with EGFR mutations
US20230321087A1 (en) 2020-09-14 2023-10-12 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
EP4213945A1 (en) 2020-09-16 2023-07-26 Janssen Biotech, Inc. Methods for treating multiple myeloma
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
TW202228775A (zh) 2020-10-14 2022-08-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物及方法
JP7633397B2 (ja) 2020-10-21 2025-02-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼の疾患の処置のための二重特異性抗ＶＥＧＦ及び抗ＴｒｋＢ結合分子
CA3200317A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
EP4623930A3 (en) 2020-12-03 2026-02-25 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
AU2022224584A1 (en) 2021-02-19 2023-09-21 Theripion, Inc. Paraoxonase fusion polypeptides and related compositions and methods
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
JP2024509920A (ja) 2021-03-09 2024-03-05 ヤンセン バイオテツク，インコーポレーテツド Ｅｇｆｒ活性化変異を欠くがんの治療
AR125290A1 (es) 2021-04-02 2023-07-05 Amgen Inc Construcciones de unión a mageb2
JP2024515396A (ja) 2021-04-14 2024-04-10 中山康方生物医▲藥▼有限公司 抗ｃｄ４７モノクローナル抗体及びその使用
TW202308689A (zh) 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物
WO2022234102A1 (en) 2021-05-06 2022-11-10 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
CA3220458A1 (en) 2021-05-18 2022-11-24 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
TW202309094A (zh) 2021-05-18 2023-03-01 美商健生生物科技公司 用於識別癌症患者以進行組合治療之方法
EP4340879A4 (en) 2021-05-20 2025-03-26 Dianthus Therapeutics OpCo, Inc. Antibodies that bind to c1s and uses thereof
JP2024522349A (ja) 2021-05-25 2024-06-18 エーデルワイス イミューン インク Ｃ－ｘ－ｃモチーフケモカイン受容体６（ｃｘｃｒ６）結合分子及びその使用方法
EP4351732A1 (en) 2021-06-09 2024-04-17 Evotec International GmbH Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
TW202317625A (zh) 2021-06-17 2023-05-01 德商百靈佳殷格翰國際股份有限公司 新穎三特異性結合分子
CN115558023A (zh) 2021-07-02 2023-01-03 安源医药科技（上海）有限公司 抗cd3抗体及其用途
WO2023287707A1 (en) 2021-07-15 2023-01-19 Just-Evotec Biologics, Inc. Bidirectional tangential flow filtration (tff) perfusion system
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
US20250270314A1 (en) 2021-08-02 2025-08-28 Tavotek Biotech (Suzhou) Ltd Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
US20250277051A1 (en) 2021-08-02 2025-09-04 Hangzhou Unogen Biotech, Ltd Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
TW202320850A (zh) 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法
EP4408468A4 (en) 2021-09-28 2025-07-02 Frontaim Biomedicines Inc MULTIPLE FORMATS OF MOLECULAR COMPLEXES
JPWO2023053282A1 (da) 2021-09-29 2023-04-06
KR20240099227A (ko) 2021-10-18 2024-06-28 타보텍 바이오테라퓨틱스 (홍콩) 리미티드 항-EGFR 항체, 항-cMET 항체, 항-VEGF 항체, 다중 특이적 항체, 및 이들의 용도
WO2023077099A1 (en) 2021-10-29 2023-05-04 Zielbio, Inc. Cancer specific plectin-1 specific antibodies and methods of use thereof
JP2024543822A (ja) 2021-11-03 2024-11-26 アフィメド ゲーエムベーハー 二重特異性ｃｄ１６ａバインダー
US20230134748A1 (en) 2021-11-03 2023-05-04 Janssen Biotech, Inc. Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
AU2022381918A1 (en) 2021-11-03 2024-06-13 Affimed Gmbh Bispecific cd16a binders
WO2023081705A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
US20250108121A1 (en) 2021-11-09 2025-04-03 Amgen Inc. Method for producing an antibody peptide conjugate
US20230183360A1 (en) 2021-12-09 2023-06-15 Janssen Biotech, Inc. Use of Amivantamab to Treat Colorectal Cancer
JP2024546914A (ja) 2021-12-15 2024-12-26 インテリウス・バイオセラピューティクス・インコーポレイテッド 偽型ウイルス粒子、それを含む組成物、及びそれらの使用
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
JP2025516245A (ja) 2022-04-29 2025-05-27 中山康方生物医▲藥▼有限公司 抗ヒトｉｌ－４ｒａの抗体及びその使用
US20230357266A1 (en) 2022-05-04 2023-11-09 Promega Corporation Photoactivatable compounds and uses thereof
IL316597A (en) 2022-05-12 2024-12-01 Amgen Res Munich Gmbh Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
IL317511A (en) 2022-06-16 2025-02-01 Cephalon Llc IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
CN117285632A (zh) 2022-06-17 2023-12-26 安源医药科技（上海）有限公司 针对tfpi的单克隆抗体及其用途
MA71324A (fr) 2022-06-30 2025-04-30 Janssen Biotech, Inc. Utilisation d'un anticorps anti-egfr/anti-met pour traiter le cancer gastrique ou oesophagien
WO2025017409A1 (en) 2023-07-14 2025-01-23 Janssen Biotech, Inc. Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies
EP4554677A1 (en) 2022-07-15 2025-05-21 Boehringer Ingelheim International GmbH Binding molecules for the treatment of cancer
CA3262768A1 (en) 2022-07-25 2024-02-01 Interius Biotherapeutics, Inc. Mutated polypeptides, compositions containing them, and their uses
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
CA3266599A1 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. UNIQUE VARIABLE DOMAIN ANTIBODIES SPECIFIC TO FENTANYL AND USE IN A CONTINUOUS AGGLUTINATION TEST
JP2025533434A (ja) 2022-09-14 2025-10-07 アムジエン・インコーポレーテツド 二重特異性分子安定化組成物
JP2025533253A (ja) 2022-10-14 2025-10-03 ヤンセン ファーマシューティカ エヌ．ベー． 抗体依存性細胞貪食の検出方法
WO2024084461A1 (en) 2022-10-21 2024-04-25 Janssen Research & Development, Llc Methods and systems for microbial detection using raman spectroscopy
WO2024084463A1 (en) 2022-10-21 2024-04-25 Janssen Research & Development, Llc Methods and systems for microbial detection using infrared spectroscopy
IL320353A (en) 2022-10-21 2025-06-01 Janssen Pharmaceutica Nv Microbial detection methods
EP4608396A1 (en) 2022-10-28 2025-09-03 Chinook Therapeutics, Inc. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
IL320562A (en) 2022-11-02 2025-07-01 Janssen Biotech Inc Cancer treatment methods
AU2023375570A1 (en) 2022-11-10 2025-06-12 Immuvia Inc Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof
AU2023385709A1 (en) 2022-11-21 2025-06-12 Dianthus Therapeutics Opco, Inc. Antibodies that bind to c1s and uses thereof
TW202436348A (zh) 2022-11-25 2024-09-16 日商中外製藥股份有限公司 蛋白質的製造方法
EP4626933A1 (en) 2022-11-30 2025-10-08 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
WO2024126294A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
WO2024126293A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
WO2024126289A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
CN120936625A (zh) 2023-01-12 2025-11-11 新加坡国立大学 用于t细胞和nk细胞恶性肿瘤的免疫疗法的cd8表达阻断和嵌合抗原受体
CN121002060A (zh) 2023-02-13 2025-11-21 英特维特国际股份有限公司 犬il-13的犬抗体
EP4665756A1 (en) 2023-02-13 2025-12-24 Intervet International B.V. Canine antibodies to canine il-4
US20240392027A1 (en) 2023-02-28 2024-11-28 Janssen Biotech Inc. Compositions comprising a bispecific gprc5d/cd3 antibody
WO2024187062A1 (en) 2023-03-08 2024-09-12 Amgen Inc. Controlled-ice nucleation lyophilization process for bispecific molecules
JP2026508945A (ja) 2023-03-13 2026-03-13 ヤンセン バイオテツク，インコーポレーテツド 二重特異性抗ＥＧＦＲ／ｃ－Ｍｅｔ抗体と抗ＰＤ－１抗体との併用療法
WO2024213635A1 (en) 2023-04-12 2024-10-17 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection
CN121358776A (zh) 2023-05-09 2026-01-16 詹森生物科技公司 包含高浓度的双特异性bcma/cd3抗体的药物组合物
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
KR20260020402A (ko) 2023-06-01 2026-02-11 얀센 바이오테크 인코포레이티드 다발성 골수종의 치료 방법
MX2025014635A (es) 2023-06-14 2026-02-03 Amgen Inc Moleculas captadoras de enmascaramiento de celulas t
CN119143869A (zh) 2023-06-16 2024-12-17 复旦大学 乙肝病毒表面抗体及其应用
TW202509078A (zh) 2023-07-07 2025-03-01 美商維里迪恩醫療股份有限公司 治療慢性甲狀腺眼病之方法
CN117186220A (zh) 2023-07-20 2023-12-08 北京伟杰信生物科技有限公司 可结合白介素31的抗体或其抗原结合片段及其制备方法和应用
WO2025050009A2 (en) 2023-09-01 2025-03-06 Children's Hospital Medical Center Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
AU2024337472A1 (en) 2023-09-05 2026-04-16 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer
WO2025079020A1 (en) 2023-10-12 2025-04-17 Janssen Biotech, Inc. First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer
WO2025094085A1 (en) 2023-10-31 2025-05-08 Janssen Biotech, Inc. Combination regimens for treating multiple myeloma
WO2025096717A1 (en) 2023-11-01 2025-05-08 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2025094107A1 (en) 2023-11-01 2025-05-08 Janssen Biotech, Inc. Methods for treating high-risk smoldering multiple myeloma
WO2025128343A1 (en) 2023-12-11 2025-06-19 Just-Evotec Biologics, Inc. Protein expression using trans-splicing and split selectable markers
WO2025136985A1 (en) 2023-12-17 2025-06-26 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2025137093A1 (en) 2023-12-19 2025-06-26 Cephalon Llc Uses for attenuated il-2 immunoconjugates
WO2025151496A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151492A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151502A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies
TW202547867A (zh) 2024-01-16 2025-12-16 美商健生生物科技公司 使用阿米維單抗治療結腸直腸癌
EP4716552A1 (en) 2024-01-22 2026-04-01 Janssen Biotech, Inc. Use of amivantamab to treat head and neck cancer
WO2025160261A2 (en) 2024-01-23 2025-07-31 Cephalon Llc Chemical dehydration and suspension delivery of protein drug products
WO2025168716A1 (en) 2024-02-07 2025-08-14 Eyebiotech Limited Compositions, doses, and methods for treatment of ocular diseases
WO2025191459A1 (en) 2024-03-11 2025-09-18 Janssen Biotech, Inc. Use of bispecific anti-egfr/c-met antibodies to treat solid tumors
WO2025226390A1 (en) 2024-04-23 2025-10-30 Cephalon Llc Use of rapamycin for improved antibody production
WO2025224681A1 (en) 2024-04-24 2025-10-30 Janssen Pharmaceutica Nv Methods and systems for microbial detection using raman and infrared spectroscopy
WO2025229538A1 (en) 2024-05-01 2025-11-06 Janssen Biotech, Inc. Materials, methods, and systems for cellular expansion of gamma delta t-cells
WO2025231372A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
US20260041768A1 (en) 2024-05-03 2026-02-12 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025243241A1 (en) 2024-05-23 2025-11-27 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2025248465A1 (en) 2024-05-29 2025-12-04 Janssen Biotech, Inc. Treatment of locally advanced or metastatic egfr-mutated non-small cell lung cancer
WO2025248505A1 (en) 2024-05-31 2025-12-04 Wayne State University Methods for treating endometrial and ovarian hyperproliferative disorders
WO2025257588A1 (en) 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
WO2025259600A2 (en) 2024-06-10 2025-12-18 University Of Rochester Brain protein targets for the treatment of migraine
WO2026022721A1 (en) 2024-07-26 2026-01-29 Janssen Biotech, Inc. Anti-tnfr2 antibodies
WO2026027944A1 (en) 2024-07-30 2026-02-05 Sairopa B.V. Anti-sirp alpha antibody formulations and uses thereof
WO2026028163A1 (en) 2024-08-01 2026-02-05 Janssen Biotech, Inc. Methods for treating high-risk smoldering multiple myeloma
WO2026033437A1 (en) 2024-08-07 2026-02-12 Janssen Biotech, Inc. Methods of treating autoimmune diseases comprising the administration of anti-bcma therapeutics
CA3278557A1 (en) 2024-08-13 2026-03-01 Janssen Biotech, Inc. Methods for reducing dermatologic adverse events in patients treated with egfr/met bispecific antibodies
WO2026038160A1 (en) 2024-08-13 2026-02-19 Janssen Biotech, Inc. Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
WO2026042017A1 (en) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc)
WO2026064732A1 (en) 2024-09-23 2026-03-26 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugate formulations
WO2026087751A1 (en) 2024-10-24 2026-04-30 Affimed Gmbh Combination of immune cell engager and nk cell products
WO2026090579A1 (en) 2024-10-25 2026-04-30 Janssen Biotech, Inc. Methods of treating smoldering multiple myeloma with ciltacabtagene autoleucel
WO2026093993A1 (en) 2024-11-01 2026-05-07 Janssen Biotech, Inc. Methods and systems for enhanced multispecific metabolic and cellular targeting

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3852304T3 (de) * 1987-03-02 1999-07-01 Enzon Labs Inc., Piscataway, N.J. Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
AU612370B2 (en) * 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins

Also Published As

Publication number Publication date
CA1341364C (en) 2002-06-04
EP0281604B1 (en) 1993-03-31
DK368588D0 (da) 1988-07-01
JPH02197A (ja) 1990-01-05
ATE87659T1 (de) 1993-04-15
EP0281604A4 (en) 1990-01-08
DE3785186D1 (de) 1993-05-06
EP0281604A1 (en) 1988-09-14
DE3785186T2 (de) 1993-07-15
WO1988001649A1 (en) 1988-03-10

Similar Documents

Publication Publication Date Title
DK368588D0 (da) Bindingsmolekyler med en enkelt plypeptidkaede
PT87138A (pt) Process for the preparation of adn recombinant molecules codin g polypeptide adn segments and of antibody compositions relate d with human tissue factor
DK1015587T3 (da) DcR3 polypeptid, en TNFR-homolog
ES2070172T3 (es) Procedimiento para producir proteinas mediante adn recombinante.
DE69412614D1 (de) Recombinante disulfid-stabilisierte polypeptide mit bindung spezifität
IL193886A (en) Antibodies that bind to ldcam sequences
ES2184728T3 (es) Proteinas de union a la fibronectina.
DK346385D0 (da) Genetiske sekvenser, hermed kodede interferon-peptider af type i og organismer, der producerer disse
DE69836823D1 (de) Jmy, mit-aktivator für p300/cbp, dafür kodierendenucleinsäure und deren verwendungen
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
DK38889D0 (da) Onkogen-indkodet polypeptid med vaekstfaktoraktivitet
DK0789763T3 (da) ICAM-4-materialer og fremgangsmåder
DE3650692D1 (de) Rekombinantes Ricin-Toxin

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment
AHS Application shelved for other reasons than non-payment
AHS Application shelved for other reasons than non-payment
AHS Application shelved for other reasons than non-payment
AHS Application shelved for other reasons than non-payment
AHS Application shelved for other reasons than non-payment